Celgene keeps M&A pipes flowing in US
US biotechnology company Celgene ensured that August got off to a roaring start for high-grade issuance with an $8bn acquisition financing this week.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts